基于TaqMan-MGB探针检测CYP2C19基因*2、*3和*17三个多态性位点的方法
卓召振 靳倩 张亮亮 匡颖 令狐克燕
贵州省人民医院医学遗传科,贵州贵阳 550002
Detection of three polymorphic sites of CYP2C19 gene * 2, * 3, and * 17 based on TaqMan-MGB probe technology
ZHUO Zhaozhen JIN Qian ZHANG Liangliang KUANG Ying LINGHU Keyan
Department of Medical Genetics, Guizhou Provincial People’s Hospital, Guizhou Province, Guiyang 550002, China
摘要 目的 建立TaqMan-MGB探针检测CYP2C19基因*2、*3和*17三个多态性位点的方法。 方法 针对CYP2C19基因*2、*3和*17位点设计合成相应引物及双标记探针。选取2021年3月至2022年6月贵州省人民医院心内科门诊已知基因型的剩余全血样本42例,覆盖每个位点的每个基因型各10例,提取DNA进行聚合酶链反应(PCR)检测,产物进行电泳和Sanger法测序分析。加样1、10、100、800 ng DNA,进行PCR检测以评价灵敏度。每个位点的每个基因型5例,每周1次对其检测,连续3周,以评价重复性。 结果 设计的引物扩增出目的基因片段,电泳显示明亮的单一的DNA条带;90个基因型的PCR结果与测序结果完全一致(P>0.05);不同加样量PCR法均可准确判读基因型,所有基因型在1 ng水平的Ct值均<34。同一基因型3次重复检测的结果一致。结论 本研究成功建立了TaqMan-MGB探针检测CYP2C19基因*2、*3和*17三个多态性位点的方法,具有快速、准确、灵敏、简便的特点。
关键词 :
TaqMan-MGB探针 ,
CYP2C19 ,
单核苷酸多态性 ,
细胞色素酶P450
Abstract :Objective To establish a method for detection of the three polymorphic sites * 2, * 3, and * 17 of CYP2C19 based on TaqMan-MGB probe technology. Methods Corresponding primers and double-labeled probes were designed for * 2, * 3 and * 17 sites of CYP2C19 gene. The remaining whole blood samples from the outpatient Department of Cardiology, Guizhou Provincial People’s Hospital from March 2021 to June 2022 with interested genotype were selected. The 42 samples containing 10 genotypes at each site were collected and the whole blood genomic DNA was extracted by polymerase chain reaction (PCR) detection, followed by electrophoresis and Sanger sequencing. 1, 10, 100, 800 ng DNA was added and PCR detection was conducted to evaluate the sensitivity. Five cases of each genotype of each locus were detected once a week for three consecutive weeks, to evaluate the repeatability. Results The designed primers successfully amplified the target gene fragment and the electrophoresis showed a bright single DNA band; the PCR results of 90 genotypes were consistent with the sequencing results (P>0.05); the genotypes could be accurately identified by PCR when different amount of DNA was added and the Ct values of all genotypes at 1 ng level were less than 34. The results of three repeated tests for the same genotype were consistent. Conclusion This study successfully establish a TaqMan-MGB probe to detect the three polymorphic sites, * 2, * 3, and * 17 of CYP2C19 gene. The method is fast, accurate, sensitive and simple.
Key words :
TaqMan-MGB probe
CYP2C19
Single nucleotide polymorphism
Cytochrome P450
基金资助: 贵州省科技计划项目(黔科合成果-LC[2021]032)。
通讯作者:
令狐克燕(1987.11-),女,硕士,主要从事细胞遗传工作。
作者简介 : 卓召振(1987.10-),男,硕士,主要从事分子诊断工作。
[1] 宋展,高鑫,吴冕,等.细胞色素P450酶的结构、功能与应用研究进展[J].微生物学通报,2020,47(7):2245-2254.
[2] Li J,Wang Y,Wang H. Distribution of CYP2C19 polymorphisms in Mongolian and Han nationals and the choice of specific antiplatelet drugs [J]. Int J Clin Pharm,2017,39(4):791-797.
[3] Manikandan P,Nagini S. Cytochrome P450 Structure,Function and Clinical Significance:A Review [J]. Curr Drug Targets,2018,19(1):38-54.
[4] Lee CR,Luzum JA,Sangkuhl K,et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy:2022 Update [J]. Clin Pharmacol Ther,2022,112(5):959-967.
[5] 周红,白文伟.关于氯吡格雷CYP2C19 基因多态性的综述[J].检验医学与临床,2017,14(2):293-297.
[6] 丁少波,张志成,崔含,等.CYP2C19多态性对动脉粥样硬化患者氯吡格雷疗效影响[J].中国卫生标准管理,2018, 9(9):72-75.
[7] Li C,Jia W,Li J,et al. Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients [J]. BMC Neurol,2021,21(1):104.
[8] Sienkiewicz-Oleszkiewicz B,Wiela-Hojeńska A. CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugs [J]. Pharmazie,2018,73(11):619-624.
[9] Botton MR,Whirl-Carrillo M,Del Tredici AL,et al. PharmVar GeneFocus:CYP2C19 [J]. Clin Pharmacol Ther,2021, 109(2):352-366.
[10] Pereira NL,Rihal CS,So DYF,et al. Clopidogrel Pharmacogenetics [J]. Circ Cardiovasc Interv,2019,12(4):e007811.
[11] Huang S,Yang S,Ly S,et al. Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms:a systematic review [J]. Eur J Clin Pharmacol,2022,78(8):1217-1225.
[12] Lyerly MJ,Bartlett K,Albright KC. Role of CYP2C19 alleles in the management of recurrent ischemic stroke [J]. Neurol Clin Pract,2019,9(2):140-144.
[13] 方莉,刘瑶,张永香,等.CYP2C19基因多态性与氯吡格雷个体化用药的相关性研究[J].川北医学院学报,2018, 33(1):70-73.
[14] 徐琴,黄盛文,杨楠楠,等.应用焦磷酸测序技术检测VKORC1和CYP2C9基因型[J].国际检验医学杂志,2018, 39(7):769-772.
[15] 夏清荣,单锋,徐亚运,等.限制性片段长度多态性聚合酶链反应法检测人细胞色素氧化酶2D6药物代谢相关基因位点多态性[J].安徽医药,2019,23(12):2347-2350.
[16] 金丽兰,蔡刚,林琳,等.Taqman-MGB法检测CYP3A5基因rs776746位点单核苷酸多态性及该位点对他克莫司代谢的影响[J].检验医学,2015,30(8):830-834.
[17] Kutyavin IV,Afonina IA,Mills A,et al. 3’-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures [J]. Nucleic Acids Res,2000,28(2):655-661.
[18] Chua EW,Maggo S,Kennedy MA. et al. Long Fragment Polymerase Chain Reaction [J]. Methods Mol Biol,2017, 1620:65-74.
[19] Hoh BL,Gong Y,Mcdonough CW,et al. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease [J]. J Neurosurg,2016, 124(6): 1746-1751.
[20] Worrall AP,Amoah V,Nevill A,et al. 103 Testing for clopidogrel and aspirin anti-platelet activity in patients with acute coronary syndromes(ACS):should we test,and if so when? [J]. Heart,2010,96(Suppl 1):A61.1-A61.
[21] 钟诗龙,韩雅玲,陈纪言,等.氯吡格雷抗血小板治疗个体化用药基因型检测指南解读[J].中国实用内科杂志,2015,35(1):38-41.
[22] 杨楠楠,徐琴,罗振元,等.焦磷酸测序检测CYP2C19基因多态性方法的建立[J].中国医药导报,2017,14(29):11-14.
[23] 吴贻晨,陈点,王尧城,等.福州地区汉族人群CYP2C19基因多态性分析及方法学比较[J].检验医学与临床,2022, 19(14):1907-1911.
[24] Ram MR,Teh X,Rajakumar T,et al. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy [J]. J Antimicrob Chemother,2019,74(1):11-16.
[25] 尹燕茹,刘国荣,潘晓华.内蒙古包头地区急性缺血性脑卒中患者CYP2C19基因多态性分析[J].中华诊断学电子杂志,2021,9(1):46-50.
[26] 林佑妮,杨敏,蓝新平.广东客家地区冠心病患者CYP2C19基因多态性分析[J].中国医药科学,2020,10(8):12-14,22.
[1]
任珊1* 任敏玮2* 戴文斌3. C反应蛋白基因多态性与肿瘤发生发展关系的研究进展 [J]. 中国医药导报, 2022, 19(13): 59-63.
[2]
李文娟 梅家平 杨勇 叶素芬. NF-κBIA基因多态性与新生儿细菌性脑膜炎易感性相关性分析 [J]. 中国医药导报, 2020, 17(6): 19-22.
[3]
赫兰1 唐晓慧2 胡嘉慧2 程栋2 王兴宇3 于勤2. 大连石城岛原驻老年居民PON1rs662基因多态性与高血压及其相关因素的关系研究 [J]. 中国医药导报, 2020, 17(24): 51-54.
[4]
郑毅1,2 贺琪2,3 李玉波4 陈家良1,2▲ 李晓东2,5. 儿童肥胖与肥胖基因单核苷酸多态性的关系研究 [J]. 中国医药导报, 2020, 17(23): 8-11,19.
[5]
李艺1 张蕾2 冯晓俊2 汪亚南1 沈爱宗2 刘圣1,2. CYP2C19基因多态性对伏立康唑不良反应发生率的影响 [J]. 中国医药导报, 2019, 16(6): 8-11.
[6]
黄玉亮 吴君荣 赵惠柳 刘志民 梁艺华 黄昭东 朱波▲. AFP基因多态性与肝细胞癌易感性的相关性研究 [J]. 中国医药导报, 2019, 16(28): 25-29.
[7]
赫兰1,2 唐伟3 于勤1,4. 血清对氧磷酶-1研究进展 [J]. 中国医药导报, 2019, 16(23): 38-40,56.
[8]
马金华1 马金兰2 王丽娟1 李进章1 沈存芳1 马金祥3. 青海地区藏族、汉族HIF-2a基因单核苷酸多态性与胃癌易感性的相关性研究 [J]. 中国医药导报, 2019, 16(12): 9-12,22.
[9]
刘文辉1 肖坚2 孙维华3 杨娜3 刘伯轩3 龚建平3. miR-1203和HOTAIR rs7958904位点对乳腺癌细胞生长的影响 [J]. 中国医药导报, 2018, 15(3): 8-12.
[10]
丁鸭锁 尹春 高广忠 鲁峻 张勤 孙兵▲. CYP2C19基因多态性与氯吡格雷ADP抑制率的关系 [J]. 中国医药导报, 2018, 15(26): 18-21.
[11]
朱丰 吴端生. 实验红鲫C1HD系SNP标记的研究 [J]. 中国医药导报, 2018, 15(19): 4-7.
[12]
范佑民1 马修平2 陈松洁1 耿德勤2▲. 氯吡格雷与SSRI类药通过CYP2C19介导的相互作用 [J]. 中国医药导报, 2018, 15(10): 51-54,67.
[13]
赵拯 宋柏力 刘赟心 邹建军 朱余兵. 中国健康受试者口服奥美拉唑肠溶胶囊的群体药动学研究 [J]. 中国医药导报, 2018, 15(1): 26-30.
[14]
赵阳阳1,2 许智慧2 刘妍2 吴荣荣3 刘新光1 徐东平2▲ 韩晋3▲. 胰岛素受体底物1 rs1801278基因多态性TaqMan-MGB双荧光探针法的建立与验证 [J]. 中国医药导报, 2017, 14(30): 4-8.
[15]
杨兴礼1 付永全1 刘小军2 张玮2 陶涛2. 肺癌全基因组关联研究进展 [J]. 中国医药导报, 2017, 14(30): 37-37.